TW202128731A - 補體抑制素(compstatin)類似物及其醫學用途 - Google Patents

補體抑制素(compstatin)類似物及其醫學用途 Download PDF

Info

Publication number
TW202128731A
TW202128731A TW109129392A TW109129392A TW202128731A TW 202128731 A TW202128731 A TW 202128731A TW 109129392 A TW109129392 A TW 109129392A TW 109129392 A TW109129392 A TW 109129392A TW 202128731 A TW202128731 A TW 202128731A
Authority
TW
Taiwan
Prior art keywords
seq
compound
trp
sar
analog
Prior art date
Application number
TW109129392A
Other languages
English (en)
Chinese (zh)
Inventor
安妮 珀尼爾 多夫頓 薛爾頓
漢利克 費雪 蒙旭
Original Assignee
丹麥商滋柏 Spv 3公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 丹麥商滋柏 Spv 3公司 filed Critical 丹麥商滋柏 Spv 3公司
Publication of TW202128731A publication Critical patent/TW202128731A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
TW109129392A 2019-08-27 2020-08-27 補體抑制素(compstatin)類似物及其醫學用途 TW202128731A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19193925.5 2019-08-27
EP19193925 2019-08-27
EP20172189.1 2020-04-29
EP20172189 2020-04-29

Publications (1)

Publication Number Publication Date
TW202128731A true TW202128731A (zh) 2021-08-01

Family

ID=72178552

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109129392A TW202128731A (zh) 2019-08-27 2020-08-27 補體抑制素(compstatin)類似物及其醫學用途

Country Status (14)

Country Link
US (1) US20220306695A1 (cg-RX-API-DMAC10.html)
EP (2) EP4272751B1 (cg-RX-API-DMAC10.html)
JP (1) JP7711044B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220066287A (cg-RX-API-DMAC10.html)
CN (1) CN114630836A (cg-RX-API-DMAC10.html)
AU (1) AU2020338688B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022003760A2 (cg-RX-API-DMAC10.html)
CA (1) CA3148536A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022003556A2 (cg-RX-API-DMAC10.html)
ES (1) ES3049784T3 (cg-RX-API-DMAC10.html)
IL (1) IL290858A (cg-RX-API-DMAC10.html)
MX (1) MX2022002433A (cg-RX-API-DMAC10.html)
TW (1) TW202128731A (cg-RX-API-DMAC10.html)
WO (1) WO2021037942A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020017385A2 (pt) * 2018-02-27 2020-12-15 Zp Spv 3 K/S Análogos de compstatina, métodos e seus usos médicos
JP2023538807A (ja) * 2020-07-16 2023-09-12 セッドぺー エスぺーヴェー 3 カー/エス 補体因子c3の阻害剤及びそれらの医学的使用
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2023048151A1 (ja) * 2021-09-22 2023-03-30 塩野義製薬株式会社 ウイルス増殖阻害活性を有する環状ペプチド
EP4622992A1 (en) * 2022-11-24 2025-10-01 Amyndas Pharmaceuticals US LLC Compstatin analogs for vector-based therapy
WO2026112532A1 (en) * 2024-11-22 2026-05-28 Apellis Pharmaceuticals, Inc. Compstatin analogs
US20260234189A1 (en) 2025-01-24 2026-08-13 Boehringer Ingelheim International Gmbh Novel and stable compstatin analogues

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505068A (ja) 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
WO1999013899A1 (en) * 1997-09-17 1999-03-25 Trustees Of The University Of Pennsylvania Peptides and peptidomimetics for inhibiting complement activation
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CA2361830A1 (en) 1999-03-17 2000-09-21 Novo Nordisk A/S Method for acylating peptides and novel acylating agents
US7989589B2 (en) 2002-09-20 2011-08-02 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved activity
CN101325963B (zh) 2005-10-08 2016-01-27 博泰迪亚制药公司 用于眼部病症的补体抑制素和其类似物
ES2390828T3 (es) 2005-11-28 2012-11-16 The Trustees Of The University Of Pennsylvania Análogos potentes de la compstatina
WO2008153963A1 (en) 2007-06-08 2008-12-18 The Trustees Of The University Of Pennsylvania Structure of compstatin-c3 complex and use for rational drug design
WO2010039690A1 (en) * 2008-09-30 2010-04-08 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
CA2813049A1 (en) * 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
PL2753636T3 (pl) 2011-09-07 2020-05-18 The Trustees Of The University Of Pennsylvania Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych
WO2014100407A1 (en) * 2012-12-19 2014-06-26 The Regents Of The University Of California Compstatin analogs
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US20180057538A1 (en) * 2016-08-26 2018-03-01 The Regents Of The University Of California Potent and highly soluble pegylated compstatin peptides
BR112020017385A2 (pt) * 2018-02-27 2020-12-15 Zp Spv 3 K/S Análogos de compstatina, métodos e seus usos médicos

Also Published As

Publication number Publication date
IL290858A (en) 2022-04-01
EP4272751B1 (en) 2025-09-24
US20220306695A1 (en) 2022-09-29
CO2022003556A2 (es) 2022-05-20
KR20220066287A (ko) 2022-05-24
JP2022545916A (ja) 2022-11-01
JP7711044B2 (ja) 2025-07-22
EP4021921A1 (en) 2022-07-06
ES3049784T3 (en) 2025-12-18
EP4272751C0 (en) 2025-09-24
WO2021037942A1 (en) 2021-03-04
EP4272751A2 (en) 2023-11-08
MX2022002433A (es) 2022-05-19
AU2020338688A1 (en) 2022-03-24
CA3148536A1 (en) 2021-03-04
EP4272751A3 (en) 2024-02-14
AU2020338688B2 (en) 2026-06-04
BR112022003760A2 (pt) 2022-05-31
CN114630836A (zh) 2022-06-14

Similar Documents

Publication Publication Date Title
US12600749B2 (en) Compstatin analogues and their medical uses
JP7711044B2 (ja) コンプスタチン類似体及びその医学的使用
JP2020128443A (ja) インターロイキン23受容体の経口ペプチド阻害剤および炎症性腸疾患を処置するためのそれらの使用
US20230287051A1 (en) Inhibitors of complement factor c3 and their medical uses
AU2012304442B2 (en) Compstatin analogs with improved pharmacokinetic properties
TW200902068A (en) GLP-1 peptide having sugar chain attached thereto
US10213476B2 (en) Compstatin analogs with improved potency and pharmacokinetic properties
US11975040B2 (en) Plexin binding regulator
HK40102364A (en) Compstatin analogues and their medical uses
AU2018275270B2 (en) Peptide PAC1 antagonists
EA049126B1 (ru) Аналоги компстатина и пути их медицинского применения
HK40102364B (en) Compstatin analogues and their medical uses
HK40092906A (en) Inhibitors of complement factor c3 and their medical uses
EA051613B1 (ru) Ингибиторы фактора с3 системы комплемента и варианты их применения в медицине